A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors

What is the purpose of this trial?

The purpose of this study is to determine the safety, preliminary evidence of clinical activity, and recommended Phase 2 dose (RP2D) of INCMGA00012 in combination with other agents that may improve the therapeutic efficacy of anti-PD-1 monotherapy.


Participation Guidelines

Ages: 18 years and older

Gender: Both


Incyte Corporation

Start Date: 02/12/2019

End Date: 08/31/2021

Last Updated: 02/13/2019

Study HIC#: 2000023802

Get Involved

For more information about this study, contact:
Stephanie Rosini
+1 203-785-2963
stephanie.vetter@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image

Investigators

Patricia LoRusso

Principal Investigator

Sub-Investigators